Newmarket Scientific
Newmarket Scientific

NEWS: New antibody for Alzheimer’s research: Learn how the enzyme CYP46A1 controls brain cholesterol levels

Brain cholesterol is an important membrane building component of glial cells, neurons and myelin sheaths. Unable to cross the blood-brain-barrier, cholesterol is synthesised in situ, transported between the various cells and eliminated via oxidative pathways to maintain appropriate levels.


Key to regulating brain cholesterol homeostasis the CNS-specific cytochrome P450 enzyme, cholesterol 24-hydroxylase (CYP46A1) is mostly expressed in the brain, converting excess cholesterol to membrane-permeable oxysterol, 24S-hydroxycholesterol (24HC). This oxidised product diffuses through the blood-brain-barrier and enters the systemic circulation to reach the liver where it is further degraded to bile acids.


Accumulation of cholesterol in the brain activates beta and gamma secretases, resulting in an increased production of amyloid beta. As CYP46A1 plays a major role in the regulation of brain cholesterol levels, it is thought to be implicated in the pathogenesis and progression of neurodegenerative disorders such Alzheimer’s disease and vascular dementia.


Check out our new anti-CYP46A1 antibody from our NS Reagents range (link below). It can be used in Western Blotting and Immunohistochemistry with human, mouse and rat samples.



Other products you may also like:


Other CYP46A1 antibodies


NS reagents: Anti-CYP46A1 antibody Applications: WB IHC  -  Reactivity: Hu Ms Rt


NS reagents: Anti-CYP7B1 Antibody Applications: ELISA IHC WB Reactivity: Hu

(Cytochrome P450 7B1/cholesterol 7 alpha-hydroxylase)


Find other antibodies for your research using the search box at the top of the page.






A Crosstalk Between Brain Cholesterol Oxidation and Glucose Metabolism in Alzheimer’s Disease, Gamba P et al, Front Neurosci. 2019; 13: 556. Published online 2019 May 31 

Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases, Petrov A M et al, Neurotherapeutics. 2019 Apr 18. doi: 10.1007/s13311-019-00731-6.

Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients